150 related articles for article (PubMed ID: 35871860)
1. [New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
Minot-This MS; Deleuze A
Bull Cancer; 2022 Oct; 109(10):988-989. PubMed ID: 35871860
[No Abstract] [Full Text] [Related]
2. Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States".
Sorscher S
Adv Ther; 2023 Sep; 40(9):4111-4113. PubMed ID: 37432550
[No Abstract] [Full Text] [Related]
3. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
Rizzo A; Palmiotti G
Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
Shah M; Osgood CL; Amatya AK; Fiero MH; Pierce WF; Nair A; Herz J; Robertson KJ; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Dec; 28(24):5249-5253. PubMed ID: 35925043
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Guven DC; Taban H; Dizdar O
J Oncol Pharm Pract; 2022 Jan; 28(1):203-204. PubMed ID: 34628993
[No Abstract] [Full Text] [Related]
10. Pembrolizumab in Early Triple-Negative Breast Cancer.
Ganguly S; Gogia A
N Engl J Med; 2022 May; 386(18):1771. PubMed ID: 35507497
[No Abstract] [Full Text] [Related]
11. Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
Olivier T; Prasad V
Ann Oncol; 2023 Aug; 34(8):723-724. PubMed ID: 37423675
[No Abstract] [Full Text] [Related]
12. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
van Dongen MGJ; Kok M
Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
[No Abstract] [Full Text] [Related]
13. [Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer].
Dierks F; Pietsch E; Dunst J
Strahlenther Onkol; 2020 Sep; 196(9):841-843. PubMed ID: 32561940
[No Abstract] [Full Text] [Related]
14. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
17. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
[TBL] [Abstract][Full Text] [Related]
18. A Case of Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Metaplastic Breast Cancer.
Gul A; Alberty-Oller JJ; Sandhu J; Ayala-Bustamante E; Adams S
JCO Precis Oncol; 2023 May; 7():e2200506. PubMed ID: 37196220
[No Abstract] [Full Text] [Related]
19. When and how do I use neoadjuvant chemotherapy for breast cancer?
Rapoport BL; Demetriou GS; Moodley SD; Benn CA
Curr Treat Options Oncol; 2014 Mar; 15(1):86-98. PubMed ID: 24306808
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.
Kharel Z; Nemer OP; Xi W; Upadhayaya B; Falkson CI; O'Regan RM; Dhakal A
Breast Dis; 2022; 41(1):255-260. PubMed ID: 35599460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
